Text Size

Platelet Activation in Chronic Inflammatory Skin Diseases

This study is not yet open for participant recruitment.
Verified December 2012 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01759693
First received: December 28, 2012
Last updated: January 2, 2013
Last verified: December 2012
History of Changes
  Purpose

Platelets are blood cells that are important in coagulation of the blood. These cells have recently been shown to play a role in a number of other biologic processes, for example inflammation. In this study the investigators will determine the extent of platelet activation in people suffering from common chronic skin inflammation-urticaria and allergic dermatitis.


Condition Intervention
Urticaria
Atopic Dermatitis
 Procedure: Blood sampling

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • Platelet activation [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Platelet function will be assessed at enrollment


Secondary Outcome Measures:
  • Mean platelet volume [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Mean platelet volume will be assessed at enrollment


Estimated Enrollment: 80
Study Start Date: February 2013
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Skin disease
Patients with urticaria or atopic dermatitis
 Procedure: Blood sampling
Blood sampling
Control
Healthy volunteers
 Procedure: Blood sampling
Blood sampling

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Hospital clinic

Criteria

Inclusion Criteria: Urticaria or atopic dermatitis -

Exclusion Criteria:Lack of informed consent

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01759693

Locations
Israel
Meir Medical Center Not yet recruiting
Kfar Saba, Israel, 44281
Contact: Martin H Ellis, MD     972-9-7471822     martinel@clalit.org.il    
Sub-Investigator: Martin H Ellis, MD            
Sponsors and Collaborators
Meir Medical Center
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01759693     History of Changes
Other Study ID Numbers: 0113, MMC 0113
Study First Received: December 28, 2012
Last Updated: January 2, 2013
Health Authority: Israel: Ethics Commission

Keywords provided by Meir Medical Center:
Platelet activation

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Urticaria
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
 Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Skin Diseases, Vascular

ClinicalTrials.gov processed this record on May 19, 2013